125 related articles for article (PubMed ID: 7666077)
21. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.
Small EJ; Meyer M; Marshall ME; Reyno LM; Meyers FJ; Natale RB; Lenehan PF; Chen L; Slichenmyer WJ; Eisenberger M
J Clin Oncol; 2000 Apr; 18(7):1440-50. PubMed ID: 10735891
[TBL] [Abstract][Full Text] [Related]
22. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
Bowden CJ; Figg WD; Dawson NA; Sartor O; Bitton RJ; Weinberger MS; Headlee D; Reed E; Myers CE; Cooper MR
Cancer Chemother Pharmacol; 1996; 39(1-2):1-8. PubMed ID: 8995493
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer.
Tu SM; Pagliaro LC; Banks ME; Amato RJ; Millikan RE; Bugazia NA; Madden T; Newman RA; Logothetis CJ
Clin Cancer Res; 1998 May; 4(5):1193-201. PubMed ID: 9607577
[TBL] [Abstract][Full Text] [Related]
24. Suramin: rapid loading and weekly maintenance regimens for cancer patients.
van Rijswijk RE; van Loenen AC; Wagstaff J; Meijer E; Lopez R; van Groeningen CJ; Heimans JJ; Pinedo HM
J Clin Oncol; 1992 Nov; 10(11):1788-94. PubMed ID: 1403059
[TBL] [Abstract][Full Text] [Related]
25. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.
Myers C; Cooper M; Stein C; LaRocca R; Walther MM; Weiss G; Choyke P; Dawson N; Steinberg S; Uhrich MM
J Clin Oncol; 1992 Jun; 10(6):881-9. PubMed ID: 1375283
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
Hudes GR; Nathan F; Khater C; Haas N; Cornfield M; Giantonio B; Greenberg R; Gomella L; Litwin S; Ross E; Roethke S; McAleer C
J Clin Oncol; 1997 Sep; 15(9):3156-63. PubMed ID: 9294479
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
[TBL] [Abstract][Full Text] [Related]
28. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.
Small EJ; McMillan A; Meyer M; Chen L; Slichenmyer WJ; Lenehan PF; Eisenberger M
J Clin Oncol; 2001 Mar; 19(5):1304-11. PubMed ID: 11230472
[TBL] [Abstract][Full Text] [Related]
29. Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy.
Westermann AM; Dubbelman R; Baars JP; Moolenaar WH; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2000; 46(1):57-62. PubMed ID: 10912579
[TBL] [Abstract][Full Text] [Related]
30. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
[TBL] [Abstract][Full Text] [Related]
31. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS
Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219
[TBL] [Abstract][Full Text] [Related]
32. Adaptive control with feedback strategies for suramin dosing.
Cooper MR; Lieberman R; La Rocca RV; Gernt PR; Weinberger MS; Headlee DJ; Kohler DR; Goldspiel BR; Peck CC; Myers CE
Clin Pharmacol Ther; 1992 Jul; 52(1):11-23. PubMed ID: 1623689
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of suramin in patients with metastatic renal cell carcinoma.
Dreicer R; Smith DC; Williams RD; See WA
Invest New Drugs; 1999; 17(2):183-6. PubMed ID: 10638490
[TBL] [Abstract][Full Text] [Related]
34. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
Lilenbaum RC; Miller AA; Batist G; Bernard S; Hollis DR; Rosner GL; Egorin MJ; Schilsky RL; Ratain MJ
J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
[TBL] [Abstract][Full Text] [Related]
35. Suramin treatment in hormone- and chemotherapy-refractory prostate cancer.
Garcia-Schürmann JM; Schulze H; Haupt G; Pastor J; Allolio B; Senge T
Urology; 1999 Mar; 53(3):535-41. PubMed ID: 10096380
[TBL] [Abstract][Full Text] [Related]
36. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
Lara PN; Stadler WM; Longmate J; Quinn DI; Wexler J; Van Loan M; Twardowski P; Gumerlock PH; Vogelzang NJ; Vokes EE; Lenz HJ; Doroshow JH; Gandara DR
Clin Cancer Res; 2006 Mar; 12(5):1556-63. PubMed ID: 16533781
[TBL] [Abstract][Full Text] [Related]
37. Use of adaptive control with feedback to individualize suramin dosing.
Scher HI; Jodrell DI; Iversen JM; Curley T; Tong W; Egorin MJ; Forrest A
Cancer Res; 1992 Jan; 52(1):64-70. PubMed ID: 1727387
[TBL] [Abstract][Full Text] [Related]
38. A prospective study of suramin-induced peripheral neuropathy.
Chaudhry V; Eisenberger MA; Sinibaldi VJ; Sheikh K; Griffin JW; Cornblath DR
Brain; 1996 Dec; 119 ( Pt 6)():2039-52. PubMed ID: 9010008
[TBL] [Abstract][Full Text] [Related]
39. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.
Savarese DM; Halabi S; Hars V; Akerley WL; Taplin ME; Godley PA; Hussain A; Small EJ; Vogelzang NJ
J Clin Oncol; 2001 May; 19(9):2509-16. PubMed ID: 11331330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
